ICOS<sup>+</sup>CD4 T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis

Mari Yokoi; Kosaku Murakami; Tomonori Yaguchi; Kenji Chamoto; Hiroaki Ozasa; Hironori Yoshida; Mirei Shirakashi; Katsuhiro Ito; Yoshihiro Komohara; Yukio Fujiwara; Hiromu Yano; Tatsuya Ogimoto; Daiki Hira; Tomohiro Terada; Toyohiro Hirai; Hirotake Tsukamoto

doi:10.1172/jci.insight.186483

ICOS⁺CD4 T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis

Published April 8, 2025 - More info

View PDF

Abstract

Managing immune-related adverse events (irAEs) caused by cancer immunotherapy is essential for developing effective and safer therapies. However, cellular mechanism(s) underlying organ toxicity during anti-PD-(L)1 therapy remain unclear. Here, we investigated the effect of chronological aging on anti-PD-(L)1 therapy-induced irAE-like lung toxicity, utilizing tumor-bearing aged mice. Anti-PD-(L)1 therapy facilitated ectopic infiltration of T and B cells, and antibody deposition in lung of aged but not young mice. Adoptive transfer of aged lung-derived CD4 T cells into TCR-deficient mice revealed that both pathogenic CD4 T cells and aged host environment were necessary for the irAE-inducible responses. Single-cell transcriptomics of lung-infiltrating cells in aged mice demonstrated that anti-PD-(L)1 therapy elicited ICOS⁺CD4 T-cell activation. Disruption of ICOS-ICOSL interaction attenuated germinal center B-cell differentiation and subsequent lung damage, which were overcome by local administration of IL-21 in the lung of anti-PD-1 therapy-treated aged mice. Therefore, ICOS⁺CD4 T cells elicited under aged environment exacerbated aberrant immune responses and the subsequent lung dysfunction. Consistent with the findings from mouse model, ICOS up-regulation in CD4 T cells was associated with later irAE incidence in patients with cancer. These finding will help development of useful strategies for irAE management in cancer patients, many of whom are elderly.

ICOS⁺CD4 T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis

Mari Yokoi,¹ Kosaku Murakami,¹ Tomonori Yaguchi,² Kenji Chamoto,² Hiroaki Ozasa,³ Hironori Yoshida,³ Mirei Shirakashi,⁴ Katsuhiro Ito,² Yoshihiro Komohara,⁵ Yukio Fujiwara,⁵ Hiromu Yano,⁵ Tatsuya Ogimoto,³ Daiki Hira,⁶ Tomohiro Terada,⁶ Toyohiro Hirai,³ and Hirotake Tsukamoto¹

Article tools

Metrics

Go to

ICOS+CD4 T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis

Mari Yokoi,1 Kosaku Murakami,1 Tomonori Yaguchi,2 Kenji Chamoto,2 Hiroaki Ozasa,3 Hironori Yoshida,3 Mirei Shirakashi,4 Katsuhiro Ito,2 Yoshihiro Komohara,5 Yukio Fujiwara,5 Hiromu Yano,5 Tatsuya Ogimoto,3 Daiki Hira,6 Tomohiro Terada,6 Toyohiro Hirai,3 and Hirotake Tsukamoto1

Article tools

Metrics

Go to

Sign up for email alerts

ICOS⁺CD4 T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis

Mari Yokoi,¹ Kosaku Murakami,¹ Tomonori Yaguchi,² Kenji Chamoto,² Hiroaki Ozasa,³ Hironori Yoshida,³ Mirei Shirakashi,⁴ Katsuhiro Ito,² Yoshihiro Komohara,⁵ Yukio Fujiwara,⁵ Hiromu Yano,⁵ Tatsuya Ogimoto,³ Daiki Hira,⁶ Tomohiro Terada,⁶ Toyohiro Hirai,³ and Hirotake Tsukamoto¹